ZURICH/BERLIN, Oct 13 (Reuters) - The Swiss blue-chip SMI .SSMI was seen opening 0.4% higher at 10,408 points on Tuesday, according to premarket indications from bank Julius Baer JBPRE01 .
Here are some of the main factors that may affect Swiss stocks
ROCHE ROG.S
The Swiss drugmaker plans to start selling a higher-volume COVID-19 antigen test for laboratories by the end of the year as the company expands diagnostics for the pandemic. NESN.S
Aimmune Therapeutics Inc AIMT.O shareholders have backed Nestle's $2 billion offer to gain full ownership of the first U.S.-approved peanut allergy treatment, which has struggled with a slow launch due to the COVID-19 pandemic. THERAPEUTICS RLFB.S
The Swiss company said on Tuesday that more people who received a 50-year-old drug that it is seeking to re-purpose against COVID-19 were alive beyond 60 days than were those who did not get the medicine. It is still awaiting data from randomized trials. ADEN.S
Australia's cloud-based services provider Nvoi NVO.AX on Tuesday said it had agreed a new framework agreement with Zurich-based human resource services provider Adecco Group for the provision of recruitment website management and support services. STATEMENTS
* ACHIKO AG ACHIN.S established a medtech expert advisory board and expanded its management team. Flughafen Zuerich FHZN.S reported an 81.4% drop in passenger number in September compared to the previous year. Basilea Pharmaceutica BSLN.S said it completed an early phase study of a prospective drug against urothelial cancer. BSLN.S
* Peach Property Group PEAN.S says it plans a capital increase with mandatory convertible bond with a target volume of 200 million Swiss francs, with Klaus Schmitz to be a new anchor shareholder with about 30% of the company. PEAN.S
ANALYSTS' VIEWS
* SGS SA SGSN.S : JP MORGAN SETS SEP-21 PRICE TARGET OF CHF 2,600 VS JUN-21 PRICE TARGET OF CHF 2,500
* EMMI AG EMMN.S : CREDIT SUISSE CUTS TO NEUTRAL FROM OUTPERFORM, CUTS TARGET PRICE TO CHF 920 FROM CHF 940
* GEBERIT AG GEBN.S : MORGAN STANLEY RAISES TARGET PRICE TO CHF 477 FROM CHF 464
ECONOMY
No major economic data scheduled.